Unknown

Dataset Information

0

Targeting CD22 for the Treatment of B-Cell Malignancies.


ABSTRACT: Immunotherapeutic agents play an increasingly important role in the treatment of B-cell malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though patients who relapse have few therapeutic options remaining. CD22 is a cell surface sialoglycoprotein uniquely present on B-cells and regulates B-cell function and proliferation. Thus, it is an appealing therapeutic target for autoimmune disorders and B-cell malignancies. A variety of therapies targeting CD22 have been developed, including monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, chimeric antigen receptor T cells, and bispecific antibodies. Here, we review the biology of CD22 and key therapies targeting CD22 in lymphoid malignancies.

SUBMITTER: Shah NN 

PROVIDER: S-EPMC8275043 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10566133 | biostudies-literature
| S-EPMC5458156 | biostudies-literature
| S-EPMC4182334 | biostudies-literature
| S-EPMC4360883 | biostudies-literature
| S-EPMC5061788 | biostudies-literature
| S-EPMC8363505 | biostudies-literature
| S-EPMC10557829 | biostudies-literature
| S-EPMC9837739 | biostudies-literature
| S-EPMC3575759 | biostudies-literature
| S-EPMC2890185 | biostudies-literature